Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP

Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP

Abstract Background Aquagenic pruritus (AP), an intense sensation of scratching induced after water contact, is the most troublesome aspect of BCR-ABL1-negative myeloproliferative neoplasms (MPNs). Mostly described in polycythemia vera (PV, ~ 40%), it is also present in essential thrombocythemia (ET...

Full description

Bibliographic Details
Main Authors: C. Le Gall-Ianotto, R. Verdet, E. Nowak, L. Le Roux, A. Gasse, A. Fiedler, D. Carlhant-Kowalski, P. Marcorelles, L. Misery, J. C. Ianotto
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Trials
Subjects:
Aquagenic pruritus
Myeloproliferative neoplasms
Randomized controlled trial
Aprepitant
Hydroxyzine
Online Access:https://doi.org/10.1186/s13063-021-05864-8

Internet

https://doi.org/10.1186/s13063-021-05864-8

Similar Items